UNCY Stock Gets Increased EPS Estimate from HC Wainwright

Unicycive Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its Q4 2027 EPS estimate for Unicycive Therapeutics to $0.07 from $0.04, maintaining a Buy rating and $13 price target.
  • Unicycive reported quarterly EPS of -$0.25, beating the consensus estimate of -$0.35 by $0.10.
  • Analyst views are mixed, though MarketBeat reports an overall Moderate Buy consensus and an average price target of $18.25.
  • Five stocks we like better than Unicycive Therapeutics.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright upped their Q4 2027 earnings estimates for Unicycive Therapeutics in a report released on Tuesday, November 17th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.07 for the quarter, up from their previous estimate of $0.04. HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($1.16) per share.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.10.

UNCY has been the topic of several other research reports. Wall Street Zen lowered shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Zacks Research upgraded Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Guggenheim reissued a "buy" rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Finally, B. Riley Financial restated a "buy" rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $18.25.

Read Our Latest Stock Analysis on UNCY

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $3.70 on Wednesday. Unicycive Therapeutics has a 52-week low of $3.33 and a 52-week high of $8.74. The firm has a fifty day moving average of $4.14 and a 200-day moving average of $5.90. The firm has a market capitalization of $103.05 million, a P/E ratio of -2.22 and a beta of 1.91.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Chicago Partners Investment Group LLC raised its stake in shares of Unicycive Therapeutics by 26.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company's stock valued at $105,000 after purchasing an additional 5,556 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new position in Unicycive Therapeutics in the third quarter worth about $36,000. Renaissance Technologies LLC acquired a new position in Unicycive Therapeutics in the first quarter worth about $161,000. Bank of America Corp DE grew its stake in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after purchasing an additional 29,378 shares in the last quarter. Finally, Seven Fleet Capital Management LP grew its stake in Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company's stock worth $521,000 after purchasing an additional 47,700 shares in the last quarter. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive's focus on conditions for which treatment options may be limited.

Further Reading

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Unicycive Therapeutics Right Now?

Before you consider Unicycive Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.

While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines